Overview
Beam Therapeutics Q3 net loss misses analyst expectations
Company ended Q3 2025 with $1.1 bln in cash, supporting operations into 2028
Beam progressing with BEAM-302 and BEAM-101 clinical trials
Outlook
Beam expects to report BEAM-302 trial data in early 2026
Company plans to present BEACON trial data at ASH meeting in December 2025
Beam's cash runway expected to support operations into 2028
Result Drivers
CASH POSITION - Beam ended Q3 2025 with $1.1 bln in cash, supporting operations into 2028
R&D EXPENSES - Increased R&D expenses to $109.8 mln in Q3 2025, contributing to net loss
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 License and Collaboration Revenue | $9.69 mln | ||
Q3 Net Income | Miss | -$112.72 mln | -$96.50 mln (11 Analysts) |
Q3 Operating Income | Miss | -$126.81 mln | -$107 mln (11 Analysts) |
Q3 Pretax Profit | Miss | -$112.72 mln | -$105.50 mln (9 Analysts) |
Q3 Operating Expenses | $136.50 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Beam Therapeutics Inc is $42.50, about 42.9% above its November 3 closing price of $24.25
Press Release: ID:nGNXbt2k6Y
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)